Scarica l'app Stockscreener
45.78
0.63%
-0.29
Dopo l'orario di chiusura:
45.78
Precedente Chiudi:
$46.07
Aprire:
$46.49
Volume 24 ore:
852.87K
Relative Volume:
1.48
Capitalizzazione di mercato:
$3.50B
Reddito:
$677.56M
Utile/perdita netta:
$59.01M
Rapporto P/E:
61.42
EPS:
0.7453
Flusso di cassa netto:
$136.42M
1 W Prestazione:
-0.82%
1M Prestazione:
+0.90%
6M Prestazione:
+23.40%
1 anno Prestazione:
+106.59%
Intervallo 1D:
$45.30
$46.54
Intervallo di 1 settimana:
$44.45
$47.41
Portata 52W:
$18.25
$49.12
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Nome
Kiniksa Pharmaceuticals International Plc
Settore
Telefono
(781) 431-9100
Indirizzo
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
45.78 | 3.50B | 677.56M | 59.01M | 136.42M | 0.7453 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.67B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 33.27B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.50B | 3.18B | 1.33B | 1.04B | 27.90 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-09-29 | Iniziato | TD Cowen | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-09-13 | Iniziato | Jefferies | Buy |
| 2024-05-03 | Iniziato | Wells Fargo | Overweight |
| 2020-06-29 | Reiterato | BofA Securities | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-12-12 | Reiterato | Wedbush | Outperform |
| 2018-06-19 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Kiniksa Pharmaceuticals International Plc Borsa (KNSA) Ultime notizie
Connor Clark & Lunn Investment Management Ltd. Acquires 101,666 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
FMR LLC's Strategic Acquisition of Kiniksa Pharmaceuticals Shares - GuruFocus
Kiniksa (KNSA) CFO sells 36,722 shares after exercising options - Stock Titan
Kiniksa (NASDAQ: KNSA) insider sale notice lists 36,722 shares (Rule 144) - Stock Titan
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again - MSN
Vanguard Group Inc. Trims Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shows Strong Growth and Bullish Chart Setup - ChartMill
Fisher Asset Management LLC Acquires 180,029 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals (KNSA) CMO sells 40K shares after option exercise - Stock Titan
How Investors Are Reacting To Kiniksa (KNSA) Turning ARCALYST Revenue Into Full-Year Profitability And Flexibility - simplywall.st
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Robust Growth Potential With 23% Upside - DirectorsTalk Interviews
Kiniksa (NASDAQ: KNSA) Rule 144 notice: 40,000-share cashless exercise - Stock Titan
KNSA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Prime Example of Affordable Growth (GARP) Investing - ChartMill
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Volatility - Yahoo Finance
KNSA/N Stock Price and Chart — BIVA:KNSA/N - TradingView
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference - GlobeNewswire
The Analyst Verdict: Kiniksa Pharmaceuticals In The Eyes Of 4 Experts - Benzinga
KNSA: Wells Fargo Raises Price Target and Maintains Overweight R - GuruFocus
KNSA: Wedbush Raises Price Target to $53, Maintains Outperform R - GuruFocus
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Compelling Value Investment - ChartMill
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: A Biopharma's Strong Growth Trajectory And 17.9% Upside Potential - DirectorsTalk Interviews
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Gap Down on Disappointing Earnings - Defense World
Kiniksa outlines $900M–$920M 2026 ARCALYST revenue guidance as market penetration deepens - MSN
Beyond the Balance Sheet: What SWOT Reveals About Kiniksa Pharma - GuruFocus
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
Kiniksa (KNSA) Q4 2025 Earnings Call Transcript - The Globe and Mail
Kiniksa Pharmaceuticals International, plcClass A Ordinary Shares (NQ: KNSA - The Chronicle-Journal
Kiniksa Pharmaceuticals International PLC (KNSA) Q4 2025 Earning - GuruFocus
Kiniksa Pharmaceuticals Hits New 52-Week High of USD 49.12 - Markets Mojo
Kiniksa Pharmaceuticals International Q4 Earnings Call Highlights - Yahoo Finance
Kiniksa Pharmaceuticals: A Multibagger with 140.68% Return and Strong Financial Metrics - Markets Mojo
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Down 6.3% on Feb 24 - GuruFocus
Kiniksa Pharmaceuticals International, plc 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KNSA) 2026-02-24 - Seeking Alpha
Wedbush Adjusts Kiniksa Pharmaceuticals International Price Target to $53 From $50, Maintains Outperform Rating - marketscreener.com
KNSA Reports Q4 Revenue, Expects Strong Future Growth - GuruFocus
Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates - Yahoo Finance
Kiniksa Pharmaceuticals International PLC reports results for the quarter ended December 31Earnings Summary - TradingView
KNSA: Arcalyst revenue up 62% to $677.6M in 2025, with strong outlook and expanding market reach - TradingView
Kiniksa Pharmaceuticals International : Corporate Presentation – February 2026 - marketscreener.com
Kiniksa Pharmaceuticals Swings to Q4 Net Income, Revenue Increases - marketscreener.com
Earnings Flash (KNSA) Kiniksa Pharmaceuticals International Posts Q4 EPS $0.17, vs. FactSet Est of $0.34 - marketscreener.com
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Earnings Flash (KNSA) Kiniksa Pharmaceuticals International, plc Reports Q4 Revenue $202.1M, vs. FactSet Est of $200.8M - marketscreener.com
ARCALYST drives Kiniksa (NASDAQ: KNSA) 62% 2025 revenue surge - Stock Titan
Kiniksa Pharmaceuticals Q4 Earnings Assessment - Benzinga
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution - GlobeNewswire
Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet - AOL.com
Kiniksa Pharmaceuticals International Plc Azioni (KNSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):